Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Carbapenem-resistant enterobacteriaceae wikipedia , lookup
Leptospirosis wikipedia , lookup
Hospital-acquired infection wikipedia , lookup
African trypanosomiasis wikipedia , lookup
Eradication of infectious diseases wikipedia , lookup
Oesophagostomum wikipedia , lookup
Leprosy Alert and Response Network System (LEARNS) Program objectives Facts & Figures LEARNS is the Philippines’ first mobile phone-based leprosy detection system, allowing frontline healthcare providers to send images of suspect leprosy lesions and symptoms via SMS to a specialist. This helps to reduce delays in diagnosis and treatment. How it works • Globally, in 2015, almost 211,000 people were diagnosed with leprosy, equivalent to one every two minutes. In the Philippines, around 2,000 new leprosy patients are detected each year. Launched as part of the Philippines Department of Health (DOH)-Novartis Foundation Task Force for Leprosy, LEARNS has been successfully implemented in Iloilo province. To date, more than 3,500 healthcare providers have been trained in LEARNS nationwide. • 81% of new leprosy patients occur in Brazil, India and Indonesia which are the most highly endemic countries for leprosy. In 2015, an evaluation was carried out to determine the diagnostic concordance between LEARNS and in-person diagnosis of leprosy. LEARNS proved to be a good tool for screening, with a 83% sensitivity to correctly identify suspect lesions as leprosy; and with a 77% specificity to exclude leprosy when a picture of the suspect lesions was included. © Novartis Foundation 2016 • It is estimated that 1.2 million people are visibly and irreversibly disabled by leprosy. • 1 in 11 newly diagnosed leprosy patients are children, indicating continued transmission of the disease. The Novartis Foundation’s strategy to interrupt the transmission of leprosy Despite the availability of free multidrug therapy (MDT) drastically reducing the number of leprosy patients over the past 30 years, the number of new patients diagnosed with leprosy has plateaued over the last decade at about 200,000-250,000 per year. In several countries across Asia and Africa, leprosy remains endemic in high-burden pockets. Now, the challenge of covering the last mile to make leprosy history is to interrupt its transmission. Although there are still uncertainties as to how leprosy is transmitted, one of the high risk factors is close and frequent contact with an infectious patient. Once infected, the average incubation period is about 5 years and it can take as long as 20 years for symptoms to appear. Disabilities are secondary complications which result from late diagnosis, when the nerve damage caused by leprosy is already present, or from acute inflammatory reactions that can occur at any stage. MDT has made it possible to treat patients, reduce transmission and prevent disability. Early detection and prompt treatment is currently the best approach to control the disease. Toward a world without leprosy The Novartis Foundation has been active in the fight against leprosy for 30 years. LEARNS is part of the Novartis Foundation’s focus on exploring innovative interventions to bring the world closer to the eventual goal of leprosy elimination. The strategy is based on consensus reached by a group of leading leprosy and disease elimination experts, who agree that a successful program requires: • early diagnosis and prompt treatment for all patients • tracing (also known as active screening) and post-exposure prophylaxis for contact persons of newly diagnosed patients • development of new diagnostic tools • action-oriented surveillance systems © Novartis Foundation 2016